In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Globus Medical (GMED – Research Report). The ...

Globus Medical (NYSE:GMED) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Globus Medical (GMED – Research Report), Glaukos ...

Globus Medical Inc (GMED) reports a 61% annual revenue increase and outlines strategic plans following the Nevro acquisition.

Welcome to the Globus Medical's fourth quarter and full year 2024 earnings call. At this time, all lines will be on mute, and ...

Medical device company Globus Medical (NYSE:GMED) reported Q4 CY2024 results , with sales up 6.6% year on year to $657.3 ...

Globus Medical expects full-year earnings in the range of $3.40 to $3.50 per share, with revenue in the range of $2.66 billion to $2.69 billion. This story was generated by Automated Insights ( http:/ ...

Globus Medical will acquire Nevro in an all-cash transaction. Both company boards of directors have unanimously approved the ...

Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro Corp ...

StockNews.com upgraded shares of Globus Medical (NYSE:GMED – Free Report) from a hold rating to a buy rating in a research ...

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...